Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
Sickle-cell disease (SCD) and beta thalassemia constitute worldwide public health problems. New therapies, including hydroxyurea, have attempted to augment the synthesis of fetal hemoglobin (HbF) and improve current treatment. Lenalidomide and pomalidomide are members of a class of immunomodulators used as anticancer agents. Because clinical trials have demonstrated that lenalidomide reduces or eliminates the need for transfusions in some patients with disrupted blood cell production, we investigated the effects of lenalidomide and pomalidomide on erythropoiesis and hemoglobin synthesis. We used an in vitro erythropoiesis model derived from human CD34+ progenitor cells from normal and SCD donors. We found that both compounds slowed erythroid maturation, increased proliferation of immature erythroid cells, and regulated hemoglobin transcription, resulting in potent induction of HbF without the cytotoxicity associated with other HbF inducers. When combined with hydroxyurea, pomalidomide and, to a lesser extent, lenalidomide were found to have synergistic effects on HbF upregulation. Our results elucidate what we believe to be a new mechanism of action of pomalidomide and lenalidomide and support the hypothesis that pomalidomide, used alone or in combination with hydroxyurea, may improve erythropoiesis and increase the ratio of fetal to adult hemoglobin. These findings support the evaluation of pomalidomide as an innovative new therapy for beta-hemoglobinopathies.
Celgene Corporation, San Diego, California , USA. ldeparse@celgene.com
Laure A
LA
Moutouh-de Parseval
Dominique
D
Verhelle
Emilia
E
Glezer
Kristen
K
Jensen-Pergakes
Gregory D
GD
Ferguson
Laura G
LG
Corral
Christopher L
CL
Morris
George
G
Muller
Helen
H
Brady
Kyle
K
Chan
D000755:Anemia, Sickle Cell / Q000378:metabolism* / Q000628:therapy; D018952:Antigens, CD34; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000986:Antisickling Agents / Q000494:pharmacology / Q000627:therapeutic use; D001803:Blood Transfusion; D002478:Cells, Cultured; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D041905:Erythroid Cells / Q000378:metabolism; D004920:Erythropoiesis / Q000187:drug effects*; D005319:Fetal Hemoglobin / Q000096:biosynthesis*; D006801:Humans; D006918:Hydroxyurea / Q000819:agonists / Q000494:pharmacology / Q000627:therapeutic use; D000077269:Lenalidomide; D008954:Models, Biological; D013792:Thalidomide / Q000819:agonists / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D015854:Up-Regulation / Q000187:drug effects; D017086:beta-Thalassemia / Q000378:metabolism* / Q000628:therapy
D018952:Antigens, CD34; D000970:Antineoplastic Agents; D000986:Antisickling Agents; D013792:Thalidomide; D005319:Fetal Hemoglobin; C467566:pomalidomide; D000077269:Lenalidomide; D006918:Hydroxyurea